Mgr. Pavel Šimara, Ph.D.
Total number of publications: 52
2012
-
BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response.
Leukemia & lymphoma, year: 2012, volume: 53, edition: 8, DOI
-
Flow Cytometry Analysis of Intracelular Protein
Flow Cytometry , Recent Perspectives, year: 2012, number of pages: 18 s.
2011
-
Proliferation and differentiation potential of CD133+ and CD34+ populations from the bone marrow and mobilized peripheral blood
Annals of hematology, year: 2011, volume: 90, edition: (2)
-
The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem/progenitor cells
Leukemia, year: 2011, volume: 25, edition: 7, DOI
2010
-
Dasatinib Promotes BIM Dependent Apoptosis Via MEK/ERK without Need for Permanent BCR-ABL Inhibition
Year: 2010, type: Conference abstract
-
Dasatinib suppresses MEK/ERK pathway activity without sustained BCR-ABL inhibition and promotes BIM dependent apoptosis in chronic myeloid leukaemia cells.
Year: 2010, type: Conference abstract
-
Determination of pCrkL level in chronic myeloid leukaemia cells using flow cytometry
Advances in Molecular and Cancer Biology, 2010, year: 2010
-
Stanovení intracelulární koncentrace imatinibu u CML pacientů
Year: 2010, type: Conference abstract
2009
-
Combination of mRNA and protein microarray analysis in complex cell profiling
Neoplasma, year: 2009, volume: 2/2009, edition: 56
-
MEK inhibition enhances BMS-214662-induced apoptosis in primitive CD34+ CML stem/progenitor cells.
Year: 2009, type: Conference abstract